UK-based AI drug discovery company Exscientia has penned a licensing agreement with AI-powered biopharmaceutical company GT Apeiron for its oral CDK7 inhibitor program, GTAEXS617 ('617). The company will pay USD 10 million in upfront cash, USD 10 million in upfront equity, and potential single-digit royalty payments upon the drug's commercialization.
As per the agreement, Exscientia will gain full rights to the intellectual property and full control of the CDK7 inhibitor program. This oral CDK7 inhibitor, currently in its monotherapy dose escalation phase, is being evaluated in the ELUCIDATE clinical trial for its impact on advanced solid tumors. Subsequently, in late 2024 or early 2025, the trial will shift focus to breast cancer patients, specifically HR+/HER2 cases who have progressed on CDK4/6 inhibitors.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.